Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 550 | 35607-66-0 |
Dose | Unit | Route |
---|---|---|
6 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1000 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 85 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 401.04 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.17 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.73 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.81 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 18, 1978 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 127.91 | 31.75 | 40 | 1125 | 33796 | 63454061 |
Systemic mastocytosis | 111.33 | 31.75 | 15 | 1150 | 166 | 63487691 |
Drug resistance | 61.72 | 31.75 | 21 | 1144 | 22912 | 63464945 |
Catatonia | 47.95 | 31.75 | 12 | 1153 | 4465 | 63483392 |
Pathogen resistance | 39.11 | 31.75 | 11 | 1154 | 6387 | 63481470 |
Rash maculo-papular | 37.62 | 31.75 | 16 | 1149 | 31880 | 63455977 |
Anaphylactic reaction | 31.89 | 31.75 | 18 | 1147 | 66082 | 63421775 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 76.23 | 39.87 | 29 | 823 | 32983 | 34923096 |
Drug resistance | 53.45 | 39.87 | 21 | 831 | 25906 | 34930173 |
Treatment failure | 41.59 | 39.87 | 21 | 831 | 46676 | 34909403 |
Mycobacterium chelonae infection | 40.04 | 39.87 | 8 | 844 | 807 | 34955272 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 188.54 | 28.93 | 68 | 1952 | 64176 | 79678192 |
Systemic mastocytosis | 97.14 | 28.93 | 15 | 2005 | 322 | 79742046 |
Rash maculo-papular | 69.32 | 28.93 | 32 | 1988 | 56046 | 79686322 |
Drug resistance | 61.42 | 28.93 | 27 | 1993 | 42186 | 79700182 |
Ototoxicity | 52.84 | 28.93 | 13 | 2007 | 3261 | 79739107 |
Anaphylactic shock | 49.06 | 28.93 | 22 | 1998 | 35974 | 79706394 |
Pathogen resistance | 48.81 | 28.93 | 17 | 2003 | 14325 | 79728043 |
Thrombocytopenia | 42.00 | 28.93 | 42 | 1978 | 265217 | 79477151 |
Catatonia | 36.15 | 28.93 | 12 | 2008 | 8744 | 79733624 |
Mycobacterium chelonae infection | 35.85 | 28.93 | 9 | 2011 | 2447 | 79739921 |
Treatment failure | 34.60 | 28.93 | 31 | 1989 | 170455 | 79571913 |
Anaphylactic reaction | 34.05 | 28.93 | 23 | 1997 | 83720 | 79658648 |
Circulatory collapse | 32.98 | 28.93 | 17 | 2003 | 37651 | 79704717 |
Nephropathy toxic | 32.74 | 28.93 | 14 | 2006 | 20405 | 79721963 |
None
Source | Code | Description |
---|---|---|
ATC | J01DC01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Gonorrhea | indication | 15628003 | DOID:7551 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Staphylococcal pneumonia | indication | 22754005 | |
Streptococcal septicemia | indication | 29577008 | |
Postoperative infection | indication | 33910007 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Peritonitis | indication | 48661000 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Abscess of lung | indication | 73452002 | DOID:0060317 |
Abdominal abscess | indication | 75100008 | |
Endometritis | indication | 78623009 | DOID:1002 |
Septicemia due to Bacteroides | indication | 79587009 | |
Infection of bone | indication | 111253001 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Female pelvic cellulitis | indication | 280486004 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Bacterial urinary infection | indication | 312124009 | |
Infectious disorder of joint | indication | 363162000 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Peptostreptococcus infection | indication | 135341000119101 | |
Skin and Skin Structure Clostridium Infection | indication | ||
Staphylococcus Lung Abscess | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Prevention of Perioperative Infection | indication | ||
Bacteroides Pelvic Inflammatory Disease | indication | ||
Vaginal Hysterectomy Infection Prevention | indication | ||
Peptococcus Pelvic Inflammatory Disease | indication | ||
Transurethral Prostatectomy Infection Prevention | indication | ||
Skin and Skin Structure Peptococcus Infection | indication | ||
Peptococcus Pelvic Cellulitis | indication | ||
Clostridium Pelvic Inflammatory Disease | indication | ||
Intra-Abdominal Klebsiella Abscess | indication | ||
Klebsiella Lung Abscess | indication | ||
Skin and Skin Structure Proteus Infection | indication | ||
Clostridium Endometritis | indication | ||
Clostridium Peritonitis | indication | ||
E. Coli Peritonitis | indication | ||
Haemophilus Influenzae Lung Abscess | indication | ||
Peptococcus Endometritis | indication | ||
Morganella Morganii Urinary Tract Infection | indication | ||
Staphylococcus Epidermidis Skin and Skin Structure Infection | indication | ||
Bacteroides Lung Abscess | indication | ||
Peptostreptococcus Endometritis | indication | ||
Streptococcus Lung Abscess | indication | ||
Inflammatory Disease of Female Pelvic Organs | indication | ||
Intra-Abdominal E. Coli Abscess | indication | ||
Pelvic Inflammatory Disease with Neisseria Gonorrhea | indication | ||
Clostridium Pelvic Cellulitis | indication | ||
Peptostreptococcus Pelvic Inflammatory Disease | indication | ||
Peptostreptococcus Pelvic Cellulitis | indication | ||
Bacteroides Pelvic Cellulitis | indication | ||
Staphylococcus Aureus Joint Infection | indication | ||
E. Coli Pelvic Cellulitis | indication | ||
E. Coli Endometritis | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
Bacteroides Pneumonia | indication | ||
Bacteroides Endometritis | indication | ||
Infection Prevention for GI Surgery | indication | ||
Intra-Abdominal Clostridium Abscess | indication | ||
Intra-Abdominal Bacteroides Abscess | indication | ||
Group B Streptococcus Pelvic Inflammatory Disease | indication | ||
Neisseria Gonorrhea Pelvic Cellulitis | indication | ||
Skin and Skin Structure Bacteroides Fragilis Infection | indication | ||
Cesarean Section Infection Prevention | indication | ||
Bacteroides Peritonitis | indication | ||
Providencia Urinary Tract Infection | indication | ||
E. Coli Lung Abscess | indication | ||
Acute gonococcal urethritis | off-label use | 29864006 | |
Gonorrhea of rectum | off-label use | 42746002 | |
Colitis | contraindication | 64226004 | DOID:0060180 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.54 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-lactamase | Enzyme | WOMBAT-PK | |||||||
Beta-lactamase | Enzyme | Ki | 6.85 | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | WOMBAT-PK | |||||||
Beta-lactamase | Enzyme | Ki | 6.30 | CHEMBL | |||||
Streptokinase A | Enzyme | EC50 | 5.48 | WOMBAT-PK | |||||
Beta-lactamase | Enzyme | Ki | 7 | CHEMBL |
ID | Source |
---|---|
4019665 | VUID |
N0000147757 | NUI |
D00913 | KEGG_DRUG |
33564-30-6 | SECONDARY_CAS_RN |
203118 | RXNORM |
C0007557 | UMLSCUI |
CHEBI:209807 | CHEBI |
CFX | PDB_CHEM_ID |
CHEMBL1200530 | ChEMBL_ID |
CHEMBL996 | ChEMBL_ID |
D002440 | MESH_DESCRIPTOR_UI |
DB01331 | DRUGBANK_ID |
441199 | PUBCHEM_CID |
10937 | IUPHAR_LIGAND_ID |
3397 | INN_ID |
6OEV9DX57Y | UNII |
33155 | MMSL |
37872 | MMSL |
4380 | MMSL |
82774 | MMSL |
d00094 | MMSL |
002722 | NDDF |
004843 | NDDF |
372780005 | SNOMEDCT_US |
57670008 | SNOMEDCT_US |
84165004 | SNOMEDCT_US |
4017965 | VANDF |
4019665 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9876 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 27 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9876 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 27 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9877 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9877 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9878 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9878 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3123 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 24 sections |
Cefoxitin and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3123 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 24 sections |
Cefoxitin and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3125 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 24 sections |
Cefoxitin and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-3125 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 24 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-109 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-110 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 25 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-111 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 27 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-245 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-245 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-246 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 23 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-246 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 23 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-247 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-341 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-341 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-341 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-341 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-341 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-342 | POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-342 | POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-342 | POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-342 | POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | Human Prescription Drug Label | 1 | 63323-342 | POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
Cefoxitin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66288-4100 | INJECTION, POWDER, FOR SOLUTION | 100 g | INTRAVENOUS | ANDA | 27 sections |